Federal Register #2026-17188

NCI Seeks Licensees and Co-Development Partners for T Cell Receptors Targeting HPV 6 or HPV 11

The National Cancer Institute (NCI), part of the National Institutes of Health under the Department of Health and Human Services, is seeking research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (HHS) - Products/Services Requested: - Licensing and/or research co-development partnerships for government-owned T cell receptor (TCR) technology - TCRs specifically target HPV 6 or HPV 11 antigens - Intended for use in adoptive cell therapy and other TCR-based approaches - Applications include treatment of HPV 6- or HPV 11-associated diseases such as recurrent respiratory papillomatosis (RRP) and anogenital condyloma - OEMs and Vendors: - No commercial OEMs or vendors are named; technology is developed and owned by the U.S. Government - Unique or Notable Requirements: - Technology is in pre-clinical stage with in vivo validation - Intellectual property rights are assigned to the U.S. Government - Opportunity for regulatory incentives for rare diseases (e.g., orphan drug designation, priority review, breakthrough therapy designation) - NCI is inviting both licensing and collaborative research partnerships

Description

The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens. These TCRs have potential use in adoptive cell therapy and other TCR-based approaches to treat HPV 6- or HPV 11-associated diseases including recurrent respiratory papillomatosis (RRP). The technology is in the pre-clinical stage with in vivo validation and aims to provide safe and effective therapies for patients with aggressive or pulmonary RRP refractory to standard treatments. The intellectual property rights have been assigned to the U.S. Government, and the NCI is inviting licensing and co-development research collaborations.

View original listing